M
Mark R. Marshall
Researcher at University of Auckland
Publications - 144
Citations - 4764
Mark R. Marshall is an academic researcher from University of Auckland. The author has contributed to research in topics: Dialysis & Peritoneal dialysis. The author has an hindex of 31, co-authored 142 publications receiving 4121 citations. Previous affiliations of Mark R. Marshall include Fresenius Medical Care & University of Health Sciences Antigua.
Papers
More filters
Journal ArticleDOI
Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS
Bernard Canaud,Jennifer L. Bragg-Gresham,Mark R. Marshall,S. Desmeules,Brenda W. Gillespie,Tom Depner,Preston S. Klassen,Friedrich K. Port +7 more
TL;DR: Observational results suggest that HDF may improve patient survival independently of its higher dialysis dose, and the potential benefits of HDF must be tested by controlled clinical trials before recommendations can be made for clinical practice.
Journal ArticleDOI
Relationship between Dialysis Modality and Mortality
TL;DR: Treatment with PD may be advantageous initially but may be associated with higher mortality after 12 mo, and the effect of dialysis modality on survival for an individual depends on time, age, and presence of comorbidities.
Journal ArticleDOI
Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy.
Mark R. Marshall,Thomas A. Golper,Thomas A. Golper,Mary Jo Shaver,Mary Jo Shaver,Muhammad G. Alam,Muhammad G. Alam,Dinesh Chatoth,Dinesh Chatoth +8 more
TL;DR: SLED is a viable alternative to traditional continuous renal replacement therapies for critically ill patients in whom IHD has failed or been withheld, although prospective studies directly comparing two modalities are required to define the exact role for SLED in this setting.
Journal ArticleDOI
Home Hemodialysis and Mortality Risk in Australian and New Zealand Populations
Mark R. Marshall,Carmel M. Hawley,Peter G. Kerr,Kevan R. Polkinghorne,Roger Marshall,John W M Agar,John W M Agar,Stephen P. McDonald,Stephen P. McDonald +8 more
TL;DR: There is an emerging HD dose-effect in Australia and New Zealand, with lower mortality risks associated with some of the more intensive HD regimens in these countries.
Journal ArticleDOI
Sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: towards an adequate therapy
TL;DR: Sustained low-efficiency daily diafiltration-f provides stable renal replacement therapy and good clinical outcomes and is a viable alternative to CRRT in this setting.